Novartis
12 articles
Industry NewsNovartisSTAT News
Novartis Confirms Nine Tumor Reports in Zolgensma Patients as FDA Opens Safety Probe
- Novartis has received nine tumor reports among patients treated with the SMA gene therapy Zolgensma since its 2019 approval; two show evidence of vector DNA integration.
- The FDA is evaluating whether regulatory action is needed and has extended the review to Itvisma, the intrathecal version, which has no reported tumors.
- The agency says benefits still outweigh risks, and Novartis notes integration risk is already in the label; over 6,000 patients have been treated.
Nine reports across 6,000-plus patients is a low rate, so the issue is causality: two integration cases and a GLI1 signal will decide whether this stays a label footnote. The read-across matters more than Zolgensma itself, because the same vector underpins Itvisma and other AAV programs that rely on the 'rare, already labelled' argument. Patient groups' complaints about disclosure speed add a trust cost.
Industry NewsNovartis / Ionis PharmaceuticalsSTAT News
Pelacarsen Full Data at AHA: Lp(a) Down, Events Not
- Novartis presented the full Lp(a)HORIZON results at the AHA meeting, with simultaneous NEJM publication. The antisense drug, licensed from Ionis, sharply lowered Lp(a) but did not reduce cardiovascular events versus placebo over nearly five years.
- The topline miss was disclosed in September; the full data leave the trial leader saying many in the field will be left scratching their heads.
This is the first large test of the Lp(a) hypothesis and it did not pay off, which hits the whole class: Amgen's olpasiran and Lilly's lepodisiran are running similar outcomes trials on the same premise. Two things to watch: whether the degree of Lp(a) lowering, not just direction, matters, and whether a subgroup with very high baseline Lp(a) tells a different story.
Industry NewsNovartisBioSpace
Novartis tallies nine tumor reports among Zolgensma recipients, two tied to vector integration
- Novartis says nine tumors have been reported in Zolgensma-treated patients since the 2019 approval; two show evidence of viral vector integration into DNA.
- The other seven have no established causal link to the therapy.
- Novartis notes tumor risk from integration is already in the label and that over 6,000 patients have received the therapy.
- SMA Europe says regulators are assessing the evidence.
Nine cases in 6,000-plus patients is a small number, but two with vector integration hit AAV's soft spot: durable, one-time dosing was always sold on the assumption that the vector stays episomal. Novartis can lean on the label, yet the real exposure is category-wide, since every AAV gene therapy rival and Novartis's own intrathecal follow-on will be asked the same question about long-term surveillance.
Industry NewsNovartis / BioArcticBioSpace
Novartis Ends Discovery Work With BioArctic on Brain-Delivery Technology
- Novartis has ended its discovery-stage collaboration with Sweden's BioArctic, the company behind Alzheimer's drug Leqembi.
- The 2025 agreement covered BioArctic's BrainTransporter blood-brain-barrier technology, with a $30 million initial payment and up to $772 million in milestones.
Discovery-stage terminations are cheap and common, and almost none of the $772 million headline was ever at risk, so the signal is mostly about BioArctic's brain-delivery platform not clearing Novartis's internal bar. It also loses a partner after AbbVie exited a separate alpha-synuclein pact, leaving Lilly as the other named BrainTransporter partner. A clinical proof-of-concept, not another discovery deal, is what would restore confidence in the platform.
Industry NewsNovartis / Avidity BiosciencesBioPharma Dive
Novartis Writes Down $1.9 Billion of Its Roughly $12 Billion Avidity Deal After del-desiran Miss
- Novartis will take a $1.9 billion impairment on del-desiran, the lead asset from its roughly $12 billion Avidity Biosciences acquisition, after the drug failed a late-stage trial.
- The company still hopes for approval and expects to need one more Phase 3 study.
- The charge is a partial write-down: the asset stays on the books, so more could follow if later results disappoint.
The write-down is small against the price paid, and keeping the drug alive protects the thesis that antibody-oligonucleotide conjugates can reach muscle. But a second Phase 3 means delay and cash, and it raises the cost of the deal for a company that has bought neuromuscular bets before. Watch whether the rest of Avidity's pipeline carries the valuation.
Industry NewsNovartisSTAT News
Novartis's remibrutinib cuts relapses versus teriflunomide in two pivotal MS trials
- The REMODEL-1 and REMODEL-2 Phase 3 trials compared oral BTK inhibitor remibrutinib with teriflunomide in relapsing multiple sclerosis.
- Both met the primary endpoint of lower annualized relapse rate, and MRI lesion measures also favored remibrutinib.
- Novartis reported no liver safety signal and a positive trend on disability progression, and plans regulatory submissions.
The BTK class has been hurt in MS by liver-safety worries, so a clean liver profile is as important as the relapse benefit. Teriflunomide is an easy comparator, though, and the real contest is against high-efficacy anti-CD20 antibodies and other BTK inhibitors such as Sanofi's tolebrutinib; disability data will decide where remibrutinib fits.
Industry NewsNovartis / Abogen BiosciencesFierce Biotech
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease
- Novartis gains worldwide exclusive rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager produced in vivo to reset B cells in autoimmune disease.
- The package is $575M upfront plus up to $7.2B in milestones (up to $7.8B in total) and royalties.
- Novartis also receives options on other Abogen RNA-based programs.
- The deal follows Novartis pausing an autoimmune CAR-T program after three deaths.
The $7.8B headline is mostly contingent; the $575M upfront is the real conviction signal. Landing this after pausing an autoimmune CAR-T program reads like Novartis hedging its B-cell reset thesis toward an in vivo, mRNA-delivered CD19xCD3 format. The options on other Abogen RNA programs suggest it is buying platform access, not just one asset.
Industry NewsNovartisFierce Biotech
Novartis Discontinues ALS Program After Lifonebart Misses Phase 2 Endpoints
- Novartis has discontinued development of lifonebart (VHB937), a TREM2 stabilizer/activator antibody, in amyotrophic lateral sclerosis (ALS).
- The decision follows Phase 2 ASTRALS trial results in which the drug missed both its primary and secondary endpoints.
- The study enrolled 251 patients with early-stage ALS; the primary endpoint was a composite of ventilator-free survival and change on the ALS Functional Rating Scale-Revised (ALSFRS-R), assessed at 40 weeks.
- The ALS discontinuation marks roughly the fourth pipeline setback for Novartis within about a month, part of a broader run of recent clinical disappointments.
- Lifonebart is not being abandoned entirely: Novartis continues to evaluate VHB937 in a separate, ongoing Phase 2 trial in early Alzheimer's disease.
Four pipeline setbacks in a month is a signal on Novartis's neuroscience screening bar, not just one bad trial. Either the Phase 2 go/no-go criteria were too generous or the underlying biology cases were weaker than the licensing rationale implied. On TREM2: one ALS miss doesn't kill the mechanism class — microglial-activation targets have had mixed reads across sponsors — but it does narrow the story to indication selection. The real tell is that Novartis kept the Alzheimer's Phase 2 running; that's management's actual vote on whether TREM2 biology holds, and it's the readout that will move the thesis. Watch for further neuro pruning next quarter, Alzheimer's data timing, and whether other TREM2-chasing biotech partners re-rate the target class.
Industry NewsNovartis / Avidity BiosciencesEndpoints News
Novartis' Avidity-Acquired DM1 Drug Del-Desiran Fails Phase 3 HARBOR Trial
- Del-desiran (delpacibart etedesiran), the antibody-oligonucleotide conjugate (AOC) Novartis picked up through its roughly $12B acquisition of Avidity Biosciences, failed to separate from placebo on the primary endpoint of the Phase 3 HARBOR trial.
- The 159-patient trial tested del-desiran against placebo in adults with myotonic dystrophy type 1 (DM1), a progressive muscle-wasting disease with no approved treatments.
- The primary endpoint, change in video hand opening time (vHOT) over 54 weeks, did not show a statistically significant improvement over placebo.
- Novartis said secondary and exploratory endpoints showed some evidence of clinical activity, and the company is reviewing the full dataset and plans to engage regulators on a path forward.
- Endpoints News framed the miss as Novartis' second major late-stage trial disappointment within days (following a setback for its Lp(a) drug pelacarsen), reporting that Novartis shares sank roughly 10% on the news.
The AOC platform itself isn't dead — secondary and exploratory signals suggest the biology worked, just not enough on this endpoint — but a primary miss on the lead asset from a $12B acquisition is about the worst possible first data readout for validating a new modality. Novartis bought Avidity for the platform, not just del-desiran, so the real question is whether this de-risks or re-risks the rest of the inherited AOC pipeline (cardiac, muscular dystrophy programs). Pair it with pelacarsen's stumble the same week and this reads less like bad luck than a pattern: aggressive, high-multiple platform bets hitting rocky Phase 3 data almost immediately. That's a harder story to sell investors than either miss alone, and it may cool appetite for the next big platform acquisition — Novartis' or anyone else's.
Industry NewsNovartis / Ionis PharmaceuticalsSTAT News
Novartis' Lp(a)-lowering drug pelacarsen fails cardiovascular outcomes trial
- Novartis' pelacarsen missed the primary endpoint in the Phase 3 Lp(a)HORIZON cardiovascular outcomes trial, which enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease.
- Pelacarsen is an antisense oligonucleotide, licensed from Ionis Pharmaceuticals, designed to suppress hepatic production of Lp(a), a lipid-protein particle linked to elevated cardiovascular risk.
- The drug achieved substantial lowering of Lp(a) levels in treated patients, but this biomarker reduction did not translate into a statistically significant drop in cardiovascular death, heart attack, stroke, or urgent revascularization versus placebo.
- The result is the first major late-stage setback for the emerging Lp(a)-lowering drug class, raising questions for rival programs from Amgen and Eli Lilly that use different modalities but showed larger Lp(a) reductions in earlier-stage studies.
- Novartis and Ionis had held global rights under a licensing and collaboration deal, with Ionis having discovered and advanced pelacarsen through early development before Novartis took it into Phase 3.
Pelacarsen just became the class's first hard-outcomes readout — and it missed, despite deep Lp(a) lowering. That's the uncomfortable part: this was the cleanest test yet of the Lp(a) causal hypothesis, and it didn't confirm it. Olpasiran (Amgen) and lepodisiran (Lilly) post larger percentage reductions in early studies, but bigger knockdown of the same biomarker doesn't guarantee outcomes benefit — their own outcomes trials now carry real doubt, not just execution risk. For Novartis, this was a marquee asset licensed from Ionis to anchor its cardiovascular pipeline; the miss removes a near-term blockbuster case and puts pressure on how the Ionis partnership economics get valued going forward. Biggest read-through: Lp(a) may need rethinking as a validated drug target, not just a biomarker to chase.
Industry NewsNovartisSTAT News
Novartis's Remibrutinib Succeeds in Phase III Multiple Sclerosis Trials
- Novartis reported positive topline Phase III results from the REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis, with the drug outperforming active comparator teriflunomide.
- Remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate and inflammatory brain lesions versus teriflunomide across both identically designed studies.
- The trials also showed a positive trend toward slowing disability progression, with a meaningful signal in a preplanned combined analysis.
- Safety data were reassuring, showing no liver safety signal, consistent with remibrutinib's existing profile in chronic spontaneous urticaria.
- Novartis plans to present late-breaking data at an upcoming MS conference and pursue global regulatory submissions for this indication.
Beating teriflunomide isn't the same as beating the field's real benchmark — ocrelizumab, natalizumab, the high-efficacy therapies most MS neurologists already reach for first. Still, the safety data are the real story here. Hepatotoxicity has dogged this drug class, including flags on Sanofi's rival tolebrutinib program, so a clean liver readout is a genuine differentiator, not just noise. If remibrutinib's selectivity truly spares the liver, Novartis gets real separation in the BTK race rather than a me-too label. Add this to the existing CSU approval and Novartis is building an actual platform molecule — one asset, multiple indications, shared manufacturing and commercial muscle. The number to watch next: whether that disability-progression trend holds up, since that's what actually shifts prescribing.
Industry NewsNovartis / Bristol Myers SquibbFierce Biotech
Novartis and BMS Pause Autoimmune CAR-T Trials After Safety Events
- Novartis and Bristol Myers Squibb separately paused clinical trials of experimental autologous CAR-T cell therapies being developed for autoimmune and neurological conditions, including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis and myasthenia gravis.
- Novartis halted eight studies of its candidate, rap-cel (rapcabtagene autoleucel), around August 24 after three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS), a severe systemic inflammatory reaction.
- Bristol Myers Squibb paused enrollment in trials of its own CD19-targeted CAR-T, zola-cel, describing "transient and reversible inflammatory events" markedly less severe than the deaths Novartis reported, and saying the therapy's safety profile otherwise remains consistent with other CAR-T treatments.
- Both companies said they are reviewing clinical data with independent safety boards and regulators before deciding on next steps for their affected programs.
Autoimmune CAR-T was the industry's hottest oncology-to-new-indication pivot — Kyverna, Cabaletta, Autolus and multiple academic programs are all racing the same CD19 mechanism, so this becomes a class-level scrutiny event, not just a Novartis/BMS problem. The two signals aren't equivalent: three IEC-HS deaths is a materially different regulatory conversation than BMS's "reversible" events — expect FDA to treat rap-cel far more cautiously than zola-cel, even though headlines pair them. Multi-trial pauses cost both companies precious time on programs meant to diversify beyond their legacy oncology CAR-T franchises (Kymriah, Breyanzi) into a much larger chronic-disease market. If regulators respond with class-wide holds or REMS-style safeguards, smaller autoimmune CAR-T players inherit the delay and diligence burden without the balance sheets to absorb it.